On Thursday, the Trump administration announced agreements with Eli Lilly and Novo Nordisk to reduce the prices of the companies’ GLP-1 drugs for Americans. Under the agreements, Ozempic and Wegovy will be sold at $350 per month and Zepbound for an average of $346 per month, depending on dose, when purchased through TrumpRx, a platform…
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
[Updated May 21, 2024.] 2023 may not go down as the brightest year for the pharma sector, but the entry of Novo Nordisk’s Ozempic (semaglutide) into the ranks of top-selling drugs like Keytruda, Dupixent, and Eliquis signals a new era in the treatment of metabolic disease. Novo Nordisk’s sales jumped by more than one-third in…
Lilly’s mirikizumab beats placebo in pivotal ulcerative colitis trial
Eli Lilly and Company (NYSE:LLY) announced that its interleukin-23 subunit p19 inhibitor mirikizumab achieved its primary endpoint of clinical remission at 52 weeks in the Phase 3 LUCENT-2 study. Lilly says mirikizumab is the first anti-IL23p19 to demonstrate maintenance of clinical remission in a Phase 3 ulcerative colitis study. Janssen (NYSE:JNJ) has ongoing clinical trials…